Extension Study of 1 mg/kg Pegunigalsidase Alfa in Patients With Fabry Disease

The objective of PB-102-F60 is to evaluate the long-term safety, tolerability, and efficacy
parameters of 1 mg/kg pegunigalsidase alfa every other week in adult Fabry patients who have
successfully completed studies PB-102-F20 or PB-102-F30. Patients will be enrolled to receive
1 mg/kg pegunigalsidase alfa as intravenous infusions every 2 weeks (±3 days). The duration
of treatment will be no less than 24 months and up to 48 months or until pegunigalsidase alfa
is commercially available to the patient at the discretion of the Sponsor. An interim
analysis may be performed for administrative purposes during the conduct of the study. For
the analysis, available efficacy and safety parameters will be summarized using descriptive
statistics.

Inclusion Criteria:

- Completion of study PB-102-F20 or PB-102-F30

- The patient signs informed consent

- Female patients and male patients whose co-partners are of child-bearing potential
agree to use a medically acceptable method of contraception, not including the rhythm
method. Acceptable methods of contraception include hormonal products, intrauterine
device, or male or female condoms. Contraception should be used for 1 month after
treatment termination.

Exclusion Criteria:

- Presence of any medical, emotional, behavioral or psychological condition that, in the
judgment of the Investigator and/or Medical Director, would interfere with patient
compliance with the requirements of the study.